Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Leblanc

Showing results (61-70 of 155) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology GroupSteven H Bernstein, Joseph M Unger, Michael Leblanc, et al.
Archives of Otolaryngology--Head & Neck Surgery|December 22, 2004
FDG-PET prediction of head and neck squamous cell cancer outcomesDavid L Schwartz, Joseph Rajendran, Bevan Yueh, et al.
JAMA Network Open|September 5, 2019
Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug IndicationsJoseph M Unger, Van T Nghiem, Dawn L Hershman, et al.
The American Journal of Surgical Pathology|March 15, 2014
Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative studyJames R Cook, Bryan Goldman, Raymond R Tubbs, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 13, 2018
Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by FinasterideJames Y Dai, Michael LeBlanc, Phyllis J Goodman, et al.
JAMA Oncology|March 12, 2016
The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical TrialsJoseph M Unger, William E Barlow, Scott D Ramsey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2005
New treatment options have changed the survival of patients with follicular lymphomaRichard I Fisher, Michael LeBlanc, Oliver W Press, et al.
The Canadian Journal of Hospital Pharmacy|July 8, 2026
Leadership and Managerial Development Needs of Pharmacy Leaders in Canadian Health Care Systems: Results from a National QuestionnaireHeather Naylor, Wooje Choi, Michael LeBlanc, et al.
JAMA Oncology|February 26, 2026
Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 TrialMazyar Shadman, Michael LeBlanc, Lisa Rimsza, et al.
JAMA Network Open|May 1, 2020
Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive FindingsJoseph M Unger, Charles D Blanke, Michael LeBlanc, et al.
Pageof 16

Showing results (61-70 of 155) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology GroupSteven H Bernstein, Joseph M Unger, Michael Leblanc, et al.
Archives of Otolaryngology--Head & Neck Surgery|December 22, 2004
FDG-PET prediction of head and neck squamous cell cancer outcomesDavid L Schwartz, Joseph Rajendran, Bevan Yueh, et al.
JAMA Network Open|September 5, 2019
Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug IndicationsJoseph M Unger, Van T Nghiem, Dawn L Hershman, et al.
The American Journal of Surgical Pathology|March 15, 2014
Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative studyJames R Cook, Bryan Goldman, Raymond R Tubbs, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 13, 2018
Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by FinasterideJames Y Dai, Michael LeBlanc, Phyllis J Goodman, et al.
JAMA Oncology|March 12, 2016
The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical TrialsJoseph M Unger, William E Barlow, Scott D Ramsey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2005
New treatment options have changed the survival of patients with follicular lymphomaRichard I Fisher, Michael LeBlanc, Oliver W Press, et al.
The Canadian Journal of Hospital Pharmacy|July 8, 2026
Leadership and Managerial Development Needs of Pharmacy Leaders in Canadian Health Care Systems: Results from a National QuestionnaireHeather Naylor, Wooje Choi, Michael LeBlanc, et al.
JAMA Oncology|February 26, 2026
Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 TrialMazyar Shadman, Michael LeBlanc, Lisa Rimsza, et al.
JAMA Network Open|May 1, 2020
Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive FindingsJoseph M Unger, Charles D Blanke, Michael LeBlanc, et al.
Pageof 16